Servier hands some cancer candidates to Horizon with £50M on the line

French drugmaker Servier has outlicensed some early-stage cancer treatments to Horizon Discovery, holding on to the rights to buy them back if they come through in preclinical development. Under the deal, Horizon gets a handful of novel kinase inhibitors for a range of cancer types, planning to use its screening platform to find ideal patient populations for each. Servier has the right to license back the treatments for as much as £50 million ($76.6 million) in milestone payments, and if it chooses not to, Horizon is free to find another pharma partner. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.